ArticleLipids in health and disease2025
Associations between metabolic dysfunction-associated fatty liver disease and carotid and femoral atherosclerosis: a population-based cross-sectional study.
Article in Lipids in health and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThe associations between metabolic dysfunction-associated fatty liver disease (MAFLD) and its subtypes (diabetes mellitus [DM]-MAFLD, overweight [OW]-MAFLD, and lean MAFLD) with carotid and femoral atherosclerosis are not well understood in the Chinese population.
methodsThis prospective study included participants from southeast China aged between 35-75 years. MAFLD and its subtypes, bilateral carotid and femoral intima-media thickness (CIMT, FIMT, and IMT), plaque (CP, FP, and Plaque), and atherosclerosis (CAS, FAS, and AS), were assessed using ultrasound imaging. Multivariate logistic regression analysis was used to evaluate these associations through odds ratios (ORs) and their corresponding 95% confidence intervals (CIs).
resultsA total of 5392 participants (1695 [31.4%] male) with a mean age of 55.6 ± 9.9 years were included in this study. The prevalence of CIMT, CP, CAS, FIMT, FP, FAS, IMT, plaque, and AS in the MAFLD group were 12.0%, 9.3%, 16.0%, 10.8%, 6.3%, 13.4%, 16.7%, 11.9%, and 20.8%, respectively, which were higher than that in the non-MAFLD group. After adjusting for possible confounds, CIMT was significantly associated with MAFLD (1.25[1.04, 1.50]) and DM-MAFLD (1.47[1.15, 1.89]); CP was associated with MAFLD (1.23[1.01, 1.50]) and DM-MAFLD (1.44 [1.10, 1.89]); CAS was associated with MAFLD (1.29[1.10, 1.53]) and DM-MAFLD (1.60[1.27, 2.00]); FP was associated with MAFLD (1.28[1.01, 1.63]) and DM-MAFLD (1.49[1.08, 2.05]); and plaque was associated with MAFLD (1.22[1.01, 1.46]) and DM-MAFLD (1.48[1.15, 1.89]) (P < 0.05). IMT and AS were associated with DM-MAFLD, with ORs (1.29[1.03, 1.62]) and (1.38[1.11, 1.71]), respectively (P < 0.05). These associations were more profound in male participants, those with < 7 years of education, used medication, and were smokers (P < 0.05).
conclusionsMAFLD, especially DM-MAFLD, may increase the risk of atherosclerosis (particularly in the carotid arteries). Furthermore, individual and lifestyle factors may further affect this risk.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.